TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: High-dose Statin Therapy in the Perioperative Period and DVT Prevention.
Brief Summary: This study is designed to determine if the use of atorvastatin (Lipitor), a member of the HMG coA reductase inhibitor class of drugs referred to as statins, will reduce inflammatory responses and deep vein thrombosis formation when given in high doses in the perioperative period.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Ezetimibe, Drug: Niaspan, Drug: Statin therapy, Behavioral: Standard care, Drug: Aspirin, Drug: Clopidogrel, Procedure: Percutaneous transluminal angioplasty (PTA) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Statin therapy, Behavioral: Standard care, Drug: Aspirin, Drug: Clopidogrel, Drug: Placebo Niaspan, Drug: Placebo Ezetimibe, Procedure: Percutaneous transluminal angioplasty (PTA) | Intervention Type: DRUG; Name: Ezetimibe; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Niaspan; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Statin therapy; Assigned to Arm(s): 1, 2 | Intervention Type: BEHAVIORAL; Name: Standard care; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Placebo Niaspan; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo Ezetimibe; Assigned to Arm(s): 2 | Intervention Type: PROCEDURE; Name: Percutaneous transluminal angioplasty (PTA); Assigned to Arm(s): 1, 2
B: Arm Label: Ezetimibe/simvastatin; Type: EXPERIMENTAL; Interventions: Drug: ezetimibe (+) simvastatin, Drug: atorvastatin 10 mg or simvastatin 20 mg | Arm Label: Doubling statin dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: simvastatin 40 mg or atorvastatin 20 mg, Drug: atorvastatin 10 mg or simvastatin 20 mg | Arm Label: Rosuvastatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rosuvastatin, Drug: atorvastatin 10 mg or simvastatin 20 mg | Intervention Type: DRUG; Name: ezetimibe (+) simvastatin; Assigned to Arm(s): Ezetimibe/simvastatin | Intervention Type: DRUG; Name: simvastatin 40 mg or atorvastatin 20 mg; Assigned to Arm(s): Doubling statin dose | Intervention Type: DRUG; Name: Rosuvastatin; Assigned to Arm(s): Rosuvastatin | Intervention Type: DRUG; Name: atorvastatin 10 mg or simvastatin 20 mg; Assigned to Arm(s): Doubling statin dose, Ezetimibe/simvastatin, Rosuvastatin
C: Intervention Type: DRUG; Name: atorvastatin; Assigned to Arm(s): N/A
D: Arm Label: Combination Therapy; Type: EXPERIMENTAL; Interventions: Drug: Extended release niacin, Drug: Simvastatin | Arm Label: Monotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Simvastatin | Intervention Type: DRUG; Name: Extended release niacin; Assigned to Arm(s): Combination Therapy | Intervention Type: DRUG; Name: Simvastatin; Assigned to Arm(s): Combination Therapy, Monotherapy

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, International, Double-Blinded (With In-House Blinding), GARDASIL-Controlled, Dose-Ranging Study of Octavalent Human Papillomavirus (HPV) L1 Virus-like Particle (VLP) Vaccine Administered to 16- to 23- Year-Old Women
Brief Summary: This dose-ranging study is to evaluate an investigational vaccine with the following objectives: (1) To demonstrate that the vaccine is well-tolerated in women (2) To evaluate immune responses in women who are between 16 and 23 years of age at enrollment.


Options:
A: Arm Label: 16-26 year olds 3 doses HPV Vaccine; Type: ACTIVE_COMPARATOR; Interventions: Biological: HPV (Human Papillomavirus) Vaccine | Arm Label: 3 dose 9-13 HPV Vaccine; Type: ACTIVE_COMPARATOR; Interventions: Biological: HPV (Human Papillomavirus) Vaccine | Arm Label: 2 dose 9-13 yrs HPV Vaccine; Type: ACTIVE_COMPARATOR; Interventions: Biological: HPV (Human Papillomavirus) Vaccine | Intervention Type: BIOLOGICAL; Name: HPV (Human Papillomavirus) Vaccine; Assigned to Arm(s): 16-26 year olds 3 doses HPV Vaccine, 2 dose 9-13 yrs HPV Vaccine, 3 dose 9-13 HPV Vaccine
B: Arm Label: Cervarix Group; Type: EXPERIMENTAL; Interventions: Biological: GSK580299 (Cervarix™ , HPV -16/18 L1 VLP AS04 vaccine) | Intervention Type: BIOLOGICAL; Name: GSK580299 (Cervarix™ , HPV -16/18 L1 VLP AS04 vaccine); Assigned to Arm(s): Cervarix Group
C: Arm Label: Cervarix Group; Type: EXPERIMENTAL; Interventions: Biological: GSK Biologicals' HPV-16/18 L1 AS04 vaccine (Cervarix TM) | Arm Label: Boostrix Polio → Cervarix Group; Type: EXPERIMENTAL; Interventions: Biological: Boostrix ® Polio, Biological: GSK Biologicals' HPV-16/18 L1 AS04 vaccine (Cervarix TM) | Arm Label: Cervarix + Boostrix Polio Group; Type: EXPERIMENTAL; Interventions: Biological: Boostrix ® Polio, Biological: GSK Biologicals' HPV-16/18 L1 AS04 vaccine (Cervarix TM) | Intervention Type: BIOLOGICAL; Name: Boostrix ® Polio; Assigned to Arm(s): Boostrix Polio → Cervarix Group, Cervarix + Boostrix Polio Group | Intervention Type: BIOLOGICAL; Name: GSK Biologicals' HPV-16/18 L1 AS04 vaccine (Cervarix TM); Assigned to Arm(s): Boostrix Polio → Cervarix Group, Cervarix + Boostrix Polio Group, Cervarix Group
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Biological: Comparator: Gardasil | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Biological: Comparator: octavalent HPV Vaccine - dose formulation 1 | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Biological: Comparator: octavalent HPV Vaccine - dose formulation 2 | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Biological: Comparator: octavalent HPV Vaccine - dose formulation 3 | Intervention Type: BIOLOGICAL; Name: Comparator: Gardasil; Assigned to Arm(s): 1 | Intervention Type: BIOLOGICAL; Name: Comparator: octavalent HPV Vaccine - dose formulation 1; Assigned to Arm(s): 2 | Intervention Type: BIOLOGICAL; Name: Comparator: octavalent HPV Vaccine - dose formulation 2; Assigned to Arm(s): 3 | Intervention Type: BIOLOGICAL; Name: Comparator: octavalent HPV Vaccine - dose formulation 3; Assigned to Arm(s): 4

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Conventional Infertility Therapy vs. Fast Track to IVF
Brief Summary: The purpose of this randomized prospective clinical trial is to determine whether an infertility treatment that moves quickly to In Vitro Fertilization (IVF) is more cost effective than the usual treatment strategy which includes various combinations of infertility drugs and intrauterine insemination (IUI) prior to utilizing In Vitro Fertilization.


Options:
A: Arm Label: Coenzyme Q10/CC group; Type: EXPERIMENTAL; Interventions: Drug: Coenzyme Q10, Drug: clomiphene citrate | Arm Label: CC alone group; Type: ACTIVE_COMPARATOR; Interventions: Drug: clomiphene citrate | Intervention Type: DRUG; Name: Coenzyme Q10; Assigned to Arm(s): Coenzyme Q10/CC group | Intervention Type: DRUG; Name: clomiphene citrate; Assigned to Arm(s): CC alone group, Coenzyme Q10/CC group
B: Arm Label: I.; Type: ACTIVE_COMPARATOR; Interventions: Procedure: intrauterine insemination, Procedure: infertility | Arm Label: II.; Type: ACTIVE_COMPARATOR; Interventions: Procedure: intrauterine insemination, Procedure: infertility | Intervention Type: PROCEDURE; Name: intrauterine insemination; Assigned to Arm(s): I., II. | Intervention Type: PROCEDURE; Name: infertility; Assigned to Arm(s): I., II.
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: pentoxifylline | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: pentoxifylline; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2
D: Arm Label: Berberine; Type: EXPERIMENTAL; Interventions: Drug: Berberine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Berberine; Assigned to Arm(s): Berberine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Conventional Infertility Therapy vs. Fast Track to IVF
Brief Summary: The purpose of this randomized prospective clinical trial is to determine whether an infertility treatment that moves quickly to In Vitro Fertilization (IVF) is more cost effective than the usual treatment strategy which includes various combinations of infertility drugs and intrauterine insemination (IUI) prior to utilizing In Vitro Fertilization.


Options:
A: Arm Label: Coenzyme Q10/CC group; Type: EXPERIMENTAL; Interventions: Drug: Coenzyme Q10, Drug: clomiphene citrate | Arm Label: CC alone group; Type: ACTIVE_COMPARATOR; Interventions: Drug: clomiphene citrate | Intervention Type: DRUG; Name: Coenzyme Q10; Assigned to Arm(s): Coenzyme Q10/CC group | Intervention Type: DRUG; Name: clomiphene citrate; Assigned to Arm(s): CC alone group, Coenzyme Q10/CC group
B: Arm Label: I.; Type: ACTIVE_COMPARATOR; Interventions: Procedure: intrauterine insemination, Procedure: infertility | Arm Label: II.; Type: ACTIVE_COMPARATOR; Interventions: Procedure: intrauterine insemination, Procedure: infertility | Intervention Type: PROCEDURE; Name: intrauterine insemination; Assigned to Arm(s): I., II. | Intervention Type: PROCEDURE; Name: infertility; Assigned to Arm(s): I., II.
C: Arm Label: N-Acetylcysteine; Type: EXPERIMENTAL; Interventions: Drug: N-Acetylcysteine | Arm Label: L-carnitine; Type: ACTIVE_COMPARATOR; Interventions: Drug: L-carnitine | Intervention Type: DRUG; Name: N-Acetylcysteine; Assigned to Arm(s): N-Acetylcysteine | Intervention Type: DRUG; Name: L-carnitine; Assigned to Arm(s): L-carnitine
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: pentoxifylline | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: pentoxifylline; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double Blind, Sham Controlled Trial Evaluating the Efficacy of Acupuncture in Relieving Symptoms of Chronic Prostatitis/ Chronic Pelvic Pain Syndrome
Brief Summary: Limited evidence suggests that acupuncture may help relieve symptoms of chronic prostatitis/chronic pelvic pain syndrome. This study evaluated if acupuncture twice weekly for 10 weeks would help ameliorate symptoms of CP/CPPS.


Options:
A: Arm Label: Placebo Arm; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: dustasteride arm; Type: EXPERIMENTAL; Interventions: Drug: Dutasteride | Intervention Type: DRUG; Name: Dutasteride; Assigned to Arm(s): dustasteride arm | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Arm
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: combined sono-electro-magnetic therapy (Sonodyn Medico Star) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Device: placebo therapy (Placebo Sonodyn Medico Star) | Intervention Type: DEVICE; Name: combined sono-electro-magnetic therapy (Sonodyn Medico Star); Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: placebo therapy (Placebo Sonodyn Medico Star); Assigned to Arm(s): 2
C: Intervention Type: PROCEDURE; Name: Acupuncture; Assigned to Arm(s): N/A
D: Arm Label: Global Therapeutic Massage (GTM); Type: PLACEBO_COMPARATOR; Interventions: Other: Global Therapeutic Massage (GTM) | Arm Label: Myofascial physical therapy (MPT); Type: ACTIVE_COMPARATOR; Interventions: Other: Myofascial physical therapy (MPT) | Intervention Type: OTHER; Name: Global Therapeutic Massage (GTM); Assigned to Arm(s): Global Therapeutic Massage (GTM) | Intervention Type: OTHER; Name: Myofascial physical therapy (MPT); Assigned to Arm(s): Myofascial physical therapy (MPT)

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double Blind, Sham Controlled Trial Evaluating the Efficacy of Acupuncture in Relieving Symptoms of Chronic Prostatitis/ Chronic Pelvic Pain Syndrome
Brief Summary: Limited evidence suggests that acupuncture may help relieve symptoms of chronic prostatitis/chronic pelvic pain syndrome. This study evaluated if acupuncture twice weekly for 10 weeks would help ameliorate symptoms of CP/CPPS.


Options:
A: Arm Label: Global Therapeutic Massage (GTM); Type: PLACEBO_COMPARATOR; Interventions: Other: Global Therapeutic Massage (GTM) | Arm Label: Myofascial physical therapy (MPT); Type: ACTIVE_COMPARATOR; Interventions: Other: Myofascial physical therapy (MPT) | Intervention Type: OTHER; Name: Global Therapeutic Massage (GTM); Assigned to Arm(s): Global Therapeutic Massage (GTM) | Intervention Type: OTHER; Name: Myofascial physical therapy (MPT); Assigned to Arm(s): Myofascial physical therapy (MPT)
B: Arm Label: Acupuncture; Type: EXPERIMENTAL; Interventions: Device: Acupuncture | Arm Label: placebo needle; Type: PLACEBO_COMPARATOR; Interventions: Device: placebo needle | Intervention Type: DEVICE; Name: Acupuncture; Assigned to Arm(s): Acupuncture | Intervention Type: DEVICE; Name: placebo needle; Assigned to Arm(s): placebo needle
C: Arm Label: Placebo Arm; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: dustasteride arm; Type: EXPERIMENTAL; Interventions: Drug: Dutasteride | Intervention Type: DRUG; Name: Dutasteride; Assigned to Arm(s): dustasteride arm | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Arm
D: Intervention Type: PROCEDURE; Name: Acupuncture; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: a Randomised Control Trial on Protective Ventilatory Strategy in Potential Organ Donors
Brief Summary: The aim of the study is to verify if a "PROTECTIVE" ventilatory strategy (low tidal volume and high PEEP, application of CPAP during the apnea test and recruitment maneuvers), improves lung function and increases the number of lungs eligible for transplantation.


Options:
A: Arm Label: change respiratory parameters, volume expanding; Type: EXPERIMENTAL; Interventions: Other: 300 ml Hydroxyethyl Starch 130/0.4 and Sodium Chloride Injection infusing in 15 minutes if PPV under VT 8 ml/kg was larger than 13% in the initial investigation | Intervention Type: OTHER; Name: 300 ml Hydroxyethyl Starch 130/0.4 and Sodium Chloride Injection infusing in 15 minutes if PPV under VT 8 ml/kg was larger than 13% in the initial investigation; Assigned to Arm(s): change respiratory parameters, volume expanding
B: Intervention Type: OTHER; Name: Abdominal surgery; Assigned to Arm(s): N/A
C: Arm Label: high VT group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Low tidal volume; Type: EXPERIMENTAL; Interventions: Procedure: Low tidal volume, Other: low tidal volume | Intervention Type: PROCEDURE; Name: Low tidal volume; Assigned to Arm(s): Low tidal volume | Intervention Type: PROCEDURE; Name: Low tidal volume; Assigned to Arm(s): Low tidal volume | Intervention Type: OTHER; Name: low tidal volume; Assigned to Arm(s): Low tidal volume
D: Arm Label: conventional ventilation, protective ventilation; Type: OTHER; Interventions: Procedure: change ventilation | Intervention Type: PROCEDURE; Name: change ventilation; Assigned to Arm(s): conventional ventilation, protective ventilation

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study Comparing an Eight-week Treatment of Aliskiren 75 mg, 150 mg and 300 mg to Placebo in Patients With Essential Hypertension
Brief Summary: This is a study for people diagnosed with hypertension to compare 3 doses (75 mg, 150 mg, and 300 mg) of an experimental product, aliskiren in comparison to a placebo. Each patient is in the study for 8 weeks


Options:
A: Intervention Type: DRUG; Name: aliskiren; Assigned to Arm(s): N/A
B: Arm Label: Aliskiren; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aliskiren | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aliskiren; Assigned to Arm(s): Aliskiren | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Aliskiren; Type: EXPERIMENTAL; Interventions: Drug: Aliskiren | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Aliskiren; Assigned to Arm(s): Aliskiren | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
D: Intervention Type: DRUG; Name: aliskiren; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: REcurrent VEnous Thromboembolism Risk Stratification Evaluation A Study to Develop a Clinical Prediction Rule to Predict Low Recurrence Risk in Patients With Idiopathic Venous Thromboembolism.
Brief Summary: The purpose of this study is to develop a way to predict which patients diagnosed with idiopathic blood clots can safely stop warfarin therapy after six months. We will use patient characteristics, blood test results and imaging test results to identify those patients who have the lowest risk of developing a new blood clot after warfarin is stopped.


Options:
A: N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Apixaban | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Apixaban | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Apixaban; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3
C: Intervention Type: DRUG; Name: aspirin; Assigned to Arm(s): N/A
D: Arm Label: Dabigatran; Type: EXPERIMENTAL; Interventions: Drug: Dabigatran | Arm Label: Warfarin (INR of 2.0-3.0); Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin | Intervention Type: DRUG; Name: Dabigatran; Assigned to Arm(s): Dabigatran | Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): Warfarin (INR of 2.0-3.0)

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 3: Randomised Controlled Trial of Rituximab in Active Ulcerative Colitis
Brief Summary: There is broad support for the hypothesis that Ulcerative colitis is an auto-immune disease. Rituximab is an antibody protein that removes a subgroup of white blood cells (B lymphocytes) from the circulation. These cells have the capacity to generate the auto-antibodies that typify auto-immune disease. Although Rituximab has been mainly used for treating B lymphocyte malignancies (lymphoma) it has also been used with promising results in Rheumatoid arthritis and has an excellent safety record. This is a small placebo-controlled trial to assess its efficacy and safety in patients with steroid-resistant active ulcerative colitis.


Options:
A: Arm Label: Abatacept (ABA); Type: EXPERIMENTAL; Interventions: Drug: abatacept (ABA) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: abatacept; Type: OTHER; Interventions: Drug: abatacept | Intervention Type: DRUG; Name: abatacept (ABA); Assigned to Arm(s): Abatacept (ABA) | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: abatacept; Assigned to Arm(s): abatacept
B: Arm Label: 1 (i); Type: ACTIVE_COMPARATOR; Interventions: Drug: Rituximab | Arm Label: 2 (ii); Type: PLACEBO_COMPARATOR; Interventions: Drug: Rituximab | Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): 1 (i), 2 (ii)
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Granulated mesalamine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Granulated mesalamine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
D: Arm Label: Ozanimod 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Ozanimod | Arm Label: Ozanimod 1 mg; Type: EXPERIMENTAL; Interventions: Drug: Ozanimod | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ozanimod; Assigned to Arm(s): Ozanimod 0.5 mg, Ozanimod 1 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 3: Randomised Controlled Trial of Rituximab in Active Ulcerative Colitis
Brief Summary: There is broad support for the hypothesis that Ulcerative colitis is an auto-immune disease. Rituximab is an antibody protein that removes a subgroup of white blood cells (B lymphocytes) from the circulation. These cells have the capacity to generate the auto-antibodies that typify auto-immune disease. Although Rituximab has been mainly used for treating B lymphocyte malignancies (lymphoma) it has also been used with promising results in Rheumatoid arthritis and has an excellent safety record. This is a small placebo-controlled trial to assess its efficacy and safety in patients with steroid-resistant active ulcerative colitis.


Options:
A: Arm Label: 1 (i); Type: ACTIVE_COMPARATOR; Interventions: Drug: Rituximab | Arm Label: 2 (ii); Type: PLACEBO_COMPARATOR; Interventions: Drug: Rituximab | Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): 1 (i), 2 (ii)
B: Intervention Type: DRUG; Name: Infliximab; Assigned to Arm(s): N/A
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Arm Label: Golimumab 100 mg -> 50 mg; Type: EXPERIMENTAL; Interventions: Biological: Golimumab 100 mg, Biological: Golimumab 50 mg | Arm Label: Golimumab 200 mg -> 100 mg; Type: EXPERIMENTAL; Interventions: Biological: Golimumab 100 mg, Biological: Golimumab 200 mg | Arm Label: Golimumab 400 mg -> 200 mg; Type: EXPERIMENTAL; Interventions: Biological: Golimumab 200 mg, Biological: Golimumab 400 mg | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BIOLOGICAL; Name: Golimumab 100 mg; Assigned to Arm(s): Golimumab 100 mg -> 50 mg, Golimumab 200 mg -> 100 mg | Intervention Type: BIOLOGICAL; Name: Golimumab 200 mg; Assigned to Arm(s): Golimumab 200 mg -> 100 mg, Golimumab 400 mg -> 200 mg | Intervention Type: BIOLOGICAL; Name: Golimumab 400 mg; Assigned to Arm(s): Golimumab 400 mg -> 200 mg | Intervention Type: BIOLOGICAL; Name: Golimumab 50 mg; Assigned to Arm(s): Golimumab 100 mg -> 50 mg
D: Arm Label: Vedolizumab; Type: EXPERIMENTAL; Interventions: Drug: vedolizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: vedolizumab; Assigned to Arm(s): Vedolizumab | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A